|
|
||||||||
From the Division of Neurology, Departments of Paediatrics (Dr. Minassian) and Genetics (Drs. Minassian, Ianzano, and Scherer), The Hospital for Sick Children and The University of Toronto, Canada; and the Comprehensive Epilepsy Program (Dr. Delgado-Escueta), Department of Neurology and Brain Research Institute, University of California, Los Angeles School of Medicine and West Los Angeles DVA Medical Center.
Address correspondence and reprint requests to Dr. Stephen W. Scherer, Department of Genetics, The Hospital for Sick Children and The University of Toronto, 555 University Ave., Toronto, Ontario, M5G 1X8, Canada.
Lafora disease is a teenage onset progressive myoclonus epilepsy caused by mutations in the EPM2A gene. In this report, we describe new mutations within EPM2A, review the known mutations to date to identify the most common, and describe three simple tests for prenatal and carrier screening.
Key words: Lafora diseaseEPM2ALaforinEpilepsyMutationEPM2B
This article has been cited by other articles:
![]() |
R.-M. Boustany, J. W. Britton, J. E. Parisi, and B. M. Keegan A 23-year-old man with seizures and visual deficit Neurology, January 1, 2008; 70(1): 73 - 78. [Full Text] [PDF] |
||||
![]() |
H. Lohi, J. Turnbull, X. C. Zhao, S. Pullenayegum, L. Ianzano, M. Yahyaoui, M. A. Mikati, N. P. Quinn, S. Franceschetti, F. Zara, et al. Genetic diagnosis in Lafora disease: Genotype-phenotype correlations and diagnostic pitfalls Neurology, March 27, 2007; 68(13): 996 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganesh, N. Tsurutani, T. Suzuki, K. Ueda, K. L. Agarwala, H. Osada, A. V. Delgado-Escueta, and K. Yamakawa The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain Hum. Mol. Genet., September 15, 2003; 12(18): 2359 - 2368. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Al Otaibi, B. A. Minassian, C. A. Ackerley, W. J. Logan, and S. Weiss Unusual Presentation of Lafora's Disease J Child Neurol, July 1, 2003; 18(7): 499 - 501. [Abstract] [PDF] |
||||
![]() |
S. Ganesh, A. V. Delgado-Escueta, T. Suzuki, S. Francheschetti, C. Riggio, G. Avanzini, A. Rabinowicz, S. Bohlega, J. Bailey, M. E. Alonso, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype Hum. Mol. Genet., May 16, 2002; 11(11): 1263 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Raben, M. Danon, N. Lu, E. Lee, L. Shliselfeld, A. V. Skurat, P. J. Roach, J.C. Lawrence Jr., O. Musumeci, S. Shanske, et al. Surprises of genetic engineering: A possible model of polyglucosan body disease Neurology, June 26, 2001; 56(12): 1739 - 1745. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ganesh, K. L. Agarwala, K. Ueda, T. Akagi, K. Shoda, T. Usui, T. Hashikawa, H. Osada, A. V. Delgado-Escueta, and K. Yamakawa Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes Hum. Mol. Genet., September 1, 2000; 9(15): 2251 - 2261. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Minassian, L. Ianzano, M. Meloche, E. Andermann, G. A. Rouleau, A. V. Delgado-Escueta, and S. W. Scherer Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy Neurology, August 8, 2000; 55(3): 341 - 346. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |